Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-12-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-019-00166-3 |
| _version_ | 1797209005566722048 |
|---|---|
| author | Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen |
| author_facet | Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen |
| author_sort | Hugo Marcel Vanderstichele |
| collection | DOAJ |
| description | Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD). |
| first_indexed | 2024-04-24T09:47:49Z |
| format | Article |
| id | doaj.art-83571f756cab49beacbdcbeb6dfb0727 |
| institution | Directory Open Access Journal |
| issn | 2193-8253 2193-6536 |
| language | English |
| last_indexed | 2024-04-24T09:47:49Z |
| publishDate | 2019-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj.art-83571f756cab49beacbdcbeb6dfb07272024-04-14T11:33:19ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362019-12-018S212914510.1007/s40120-019-00166-3Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical EnvironmentHugo Marcel Vanderstichele0Charlotte E. Teunissen1Eugeen Vanmechelen2BiomarkableAmsterdam University CenterKey4ADAbstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).https://doi.org/10.1007/s40120-019-00166-3AssayBloodBiomarker panelβ-AmyloidTauValidation |
| spellingShingle | Hugo Marcel Vanderstichele Charlotte E. Teunissen Eugeen Vanmechelen Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment Neurology and Therapy Assay Blood Biomarker panel β-Amyloid Tau Validation |
| title | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| title_full | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| title_fullStr | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| title_full_unstemmed | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| title_short | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| title_sort | critical steps to be taken into consideration before quantification of β amyloid and tau isoforms in blood can be implemented in a clinical environment |
| topic | Assay Blood Biomarker panel β-Amyloid Tau Validation |
| url | https://doi.org/10.1007/s40120-019-00166-3 |
| work_keys_str_mv | AT hugomarcelvanderstichele criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment AT charlotteeteunissen criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment AT eugeenvanmechelen criticalstepstobetakenintoconsiderationbeforequantificationofbamyloidandtauisoformsinbloodcanbeimplementedinaclinicalenvironment |